Branded Legacy Inc. (OTC:BLEG) Stock In Focus After Recent News

Investors are routinely on the lookout for companies that may be making major strides in particular sectors, and by that requirement, it may be a good idea to take a closer look at the innovative biotech holding company Branded Legacy Inc. (OTC:BLEG).

On March 12, the company entered the news cycle after it announced that it had completed the acquisition of the well-known plant-based pharmaceutical developer Sycamore BioPharma Inc. It was a major new milestone for the company, which would help Branded Legacy strengthen its position as a major player in the biotech sector and also help it take control of assets worth nearly $2 million.

The company would also secure important personnel who would all be key in taking forward clinical trials after the two entities came together. Sycamore BioPharma is currently regarded as one of the more active product developers in the wellness industry. The products it developed include everything from gummies to pain-relieving tropical creams and compression sleeves, among others. It was also noted in the news release that Branded Legacy would also get control of ready-to-ship high-quality inventory worth $500,000.

The Chief Executive Officer of Branded Legacy, David Oswald, spoke about the latest developments as well. He noted that everyone at the company was thrilled at the fact that Sycamore BioPharma had been added to its portfolio. He stated that it was a tactical move from the company that would augment its existing portfolio.

Additionally, the acquisition would also take Branded Legacy a step closer to the strategically important aim of being awarded FDA (United States Food and Drug Administration) approval for many of its pharmaceutical products. On the flip side, the transaction would open up new markets for the Sycamore products and make use of the sales networks that belong to Branded Legacy.